Growth • Takeda Pharmaceutical Co
TAK
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
15,2%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
14,9%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
5,7%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-4,2%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
13%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
16,9%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!